...
首页> 外文期刊>Annals of Internal Medicine >Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial.
【24h】

Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial.

机译:美托洛尔与胺碘酮预防心脏手术后心房颤动:一项随机试验。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Current guidelines recommend beta-blockers as the first-line preventive treatment of atrial fibrillation (AF) after cardiac surgery. Despite this, 19% of physicians report using amiodarone as first-line prophylaxis of postoperative AF. Data directly comparing the efficacy of these agents in preventing postoperative AF are lacking. OBJECTIVE: To determine whether intravenous metoprolol and amiodarone are equally effective in preventing postoperative AF after cardiac surgery. DESIGN: Randomized, prospective, equivalence, open-label, multicenter study. (ClinicalTrials.gov registration number: NCT00784316) SETTING: 3 cardiac care referral centers in Finland. PATIENTS: 316 consecutive patients who were hemodynamically stable and free of mechanical ventilation and AF within 24 hours after cardiac surgery. INTERVENTION: Patients were randomly assigned to receive 48-hour infusion of metoprolol, 1 to 3 mg/h, according to heart rate, or amiodarone, 15 mg/kg of body weight daily, with a maximum daily dose of 1000 mg, starting 15 to 21 hours after cardiac surgery. MEASUREMENTS: The primary end point was the occurrence of the first AF episode or completion of the 48-hour infusion. RESULTS: Atrial fibrillation occurred in 38 of 159 (23.9%) patients in the metoprolol group and 39 of 157 (24.8%) patients in the amiodarone group (P = 0.85). However, the difference (-0.9 percentage point [90% CI, -8.9 to 7.0 percentage points]) does not meet the prespecified equivalence margin of 5 percentage points. The adjusted hazard ratio of the metoprolol group compared with the amiodarone group was 1.09 (95% CI, 0.67 to 1.76). LIMITATIONS: Caregivers were not blinded to treatment allocation, and the trial evaluated only stable patients who were not at particularly elevated risk for AF. The withdrawal of preoperative beta-blocker therapy may have increased the risk for AF in the amiodarone group. CONCLUSION: The occurrence of AF was similar in the metoprolol and amiodarone groups. However, because of the wide range of the CIs, the authors cannot conclude that the 2 treatments were equally effective. PRIMARY FUNDING SOURCE: The Finnish Foundation for Cardiovascular Research and the Kuopio University EVO Foundation.
机译:背景:目前的指南建议将β受体阻滞剂作为心脏手术后房颤(AF)的一线预防性治疗。尽管如此,仍有19%的医生报告使用胺碘酮作为术后房颤的一线预防方法。缺乏直接比较这些药物预防术后房颤疗效的数据。目的:确定静脉美托洛尔和胺碘酮在预防心脏手术后房颤后是否同样有效。设计:随机,前瞻性,等效,开放标签,多中心研究。 (ClinicalTrials.gov注册号:NCT00784316)地点:芬兰的3个心脏保健转诊中心。患者:心脏手术后24小时内连续316名血液动力学稳定且无机械通气和AF的患者。干预:根据患者心率随机分配患者接受48小时美托洛尔1到3毫克/小时的输注,或胺碘酮每天15毫克/公斤体重的输注,最大每日剂量为1000毫克,开始15在心脏手术后的21小时内。测量:主要终点是首次AF发作或48小时输注完成。结果:美托洛尔组159例患者中有38例(23.9%)发生了房颤,胺碘酮组157例患者中有39例(24.8%)发生了房颤(P = 0.85)。但是,差异(-0.9个百分点[90%CI,-8.9至7.0个百分点])不符合预先指定的5个百分点的等效范围。美托洛尔组与胺碘酮组相比调整后的危险比为1.09(95%CI,0.67至1.76)。局限性:护理人员并未盲目分配治疗方案,该试验仅评估了那些没有发生AF风险特别高的稳定患者。在胺碘酮组中,术前停用β受体阻滞剂可能会增加发生房颤的风险。结论:美托洛尔和胺碘酮组房颤的发生率相似。但是,由于CI的范围很广,因此作者不能得出结论,这两种治疗方法均有效。主要资金来源:芬兰心血管研究基金会和库奥皮奥大学EVO基金会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号